CD Biosynsis offers specialized CHO (Chinese Hamster Ovary) Cells CRISPR Interference (CRISPRi) Gene Repression Services, providing tunable and reversible control over gene expression in this premier mammalian host. CHO cells are the industry standard for producing complex biotherapeutics, monoclonal antibodies (mAbs), and biosimilars. Optimizing these cell lines requires precise enzyme level control, often difficult with permanent knockouts or promoter swaps. CRISPRi, utilizing a deactivated Cas9 (dCas9) and a guide RNA (gRNA), effectively represses gene transcription without permanently altering the genome. This allows for fine-tuning metabolic pathways (e.g., maximizing energy supply), reducing flux to competing pathways (e.g., lactate production), and optimizing the expression balance of multi-enzyme systems within the CHO cell chassis. Our services are essential for predictable and efficient optimization of cell line productivity and product quality.
Get a QuoteOptimizing CHO cell metabolism and viability requires subtle adjustments to native enzyme activity. Full gene knockouts are often lethal or lead to unpredictable outcomes, especially for essential genes or regulatory factors. Our CRISPRi platform is specifically optimized for CHO cells, employing dCas9 equipped with a Nuclear Localization Signal (NLS) to efficiently access the genomic DNA. This enables reliable gene knockdown (partial repression), which is crucial for managing essential pathways (e.g., apoptosis regulation) or balancing the flux in metabolic pathways (e.g., central carbon metabolism). This capability accelerates the optimization phase by allowing for rapid, non-permanent testing of various expression levels.
Rational gRNA Design
Computational design of single guide RNAs (gRNAs) targeting promoter regions or the initial coding sequence to achieve maximal transcriptional repression efficiency in CHO cells.
Off-Target Minimization
Bioinformatics screening against the complex CHO genome to ensure gRNAs exhibit high specificity, minimizing non-specific binding and unintended functional disruption.
gRNA Library Construction
High-diversity library generation to screen multiple repression levels per target gene, allowing rapid optimization of flux for enhanced productivity (Qp).
NLS-dCas9 Delivery
Delivery of dCas9 (deactivated Cas9) equipped with a Nuclear Localization Signal (NLS) via RNP or optimized lentivirus to ensure rapid and stable targeting to the CHO cell nucleus.
Inducible Repression
Use of tightly regulated mammalian inducible promoters (e.g., Tet-On/Off system) to control dCas9 or gRNA expression, allowing for precise, time-dependent repression during fed-batch culture.
Multiplexing Capability
Design of Pol II promoters and array systems to enable the simultaneous repression of multiple metabolic genes (e.g., lactate dehydrogenase and apoptosis genes) using a single delivery method.
Lactate/Ammonia Reduction
Tunable repression of genes like LDHA (lactate dehydrogenase) or glutamine synthetase (GS) to reduce toxic byproduct accumulation and improve media longevity.
Anti-Apoptosis Tuning
Partial repression of pro-apoptotic genes (e.g., Bax, Bak) to safely extend the cell culture's productive lifespan without introducing permanent gene knockouts.
Glycosylation Pathway Balance
Repressing native glycan enzymes (e.g., sialidases) to improve glycan homogeneity and ensure the secreted therapeutic protein meets quality specifications.
A systematic process from target identification to validated, repressible cell line delivery.
1. Target Identification & Design
2. CRISPRi System Construction & Delivery
3. Clonal Isolation and Screening
4. Verification and Delivery
Identify metabolic or viability targets for repression. Design gRNA(s) for the promoter or coding sequence.
Select appropriate promoter systems (constitutive or inducible) for dCas9 and gRNA expression.
Generate gRNA library if high-throughput screening of repression levels is required.
Construct the NLS-dCas9 expression cassette and assemble the gRNA(s) into the delivery vector (RNP or lentivirus).
Deliver the CRISPRi system into the CHO host cell line via optimized electroporation or lentiviral transduction.
Select for stable integration clones (if applicable) using antibiotic selection.
Verify gene repression level via qPCR or Western Blot to confirm dCas9 efficacy.
Validate the resulting phenotype (e.g., extended viability, improved titer) under optimized bioprocessing conditions.
Delivery of the verified, repressible CHO master cell bank (MCB) and full data report.
Tunable Metabolic Control
CRISPRi provides graded repression (knockdown), allowing for fine-tuning of metabolic flux (e.g., lactate pathway) and anti-apoptosis genes without irreversible or lethal knockouts.
Non-Permanent Optimization
The repression is reversible (especially with inducible systems), which is ideal for rapidly testing and optimizing expression strategies without committing to a permanent genomic edit.
Eukaryotic Precision
Specialized NLS-dCas9 systems ensure efficient delivery and function within the mammalian nucleus, overcoming the compartmentalization barrier and minimizing off-target effects.
Accelerated Screening
The ability to screen libraries of repression levels accelerates the development process, allowing engineers to quickly identify the optimal expression balance for complex traits (e.g., viability vs. titer).
1. Why choose CRISPRi over gene knockout for metabolic tuning?
CRISPRi provides tunable, non-lethal repression (knockdown). Knocking out metabolic genes can be lethal or cause unpredictable side effects, while CRISPRi allows for partial repression to safely redirect flux (e.g., suppress lactate) while maintaining high viability.
2. How is the dCas9 transported into the CHO nucleus?
The dCas9 enzyme is fused to a Nuclear Localization Signal (NLS) tag, which actively facilitates its transport across the nuclear membrane and into the nucleus, where the genomic DNA is located.
3. Can you use CRISPRi to reduce lactate production?
Yes. We can target genes like lactate dehydrogenase (LDHA) for partial repression. This slows the conversion of pyruvate to lactate, reducing toxic byproduct accumulation and improving the longevity and productivity of the cell culture.
4. What types of inducible systems are supported for CRISPRi in CHO cells?
We support highly regulated mammalian inducible systems, most commonly the Tetracycline (Tet-On/Off) system, which allows for tight, dose-dependent control over dCas9 or gRNA expression via Doxycycline administration.
5. What is the advantage of repressing pro-apoptotic genes?
Partial repression of pro-apoptotic genes (e.g., Bax) extends the anti-apoptosis state of the CHO cells, allowing the culture to remain viable and productive for a longer period in the fed-batch bioreactor, increasing overall titer.
6. How is the repression level verified?
We use quantitative methods such as quantitative PCR (qPCR) to measure the reduction in target gene mRNA levels and Western Blot to confirm the corresponding decrease in functional protein levels in response to induction.
7. Is the dCas9 component integrated into the CHO genome?
For stable clonal cell line development, the dCas9 cassette is typically integrated into a transcriptionally active genomic locus (e.g., via lentivirus or HDR) to ensure consistent and stable expression across all cell generations.
8. What input is required to start a CRISPRi repression project?
We require the specific CHO host cell line, and the accession number or sequence of the target gene(s) you wish to repress (e.g., LDHA, BAX, or a specific protease).
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.